Filing Flows › TG Therapeutics (TGTX) › Operating margin
TG Therapeutics (TGTX) operating margin by quarter
TG Therapeutics' operating margin was 9.0% in Q2 2026 (second quarter 2026), -8.0 pts from Q1 2026. Over the last 7 quarters it ranged from 7.1% (Q1 2025) to 27.7% (Q4 2024).
| Quarter | Operating margin | Q/Q | Y/Y |
|---|---|---|---|
| Q2 2026 | 9.0% | -8.0 pts | -15.7 pts |
| Q1 2026 | 17.0% | -9.2 pts | +9.8 pts |
| Q4 2025 | 26.2% | +8.1 pts | -1.5 pts |
| Q3 2025 | 18.2% | -6.5 pts | — |
| Q2 2025 | 24.7% | +17.6 pts | — |
| Q1 2025 | 7.1% | -20.5 pts | — |
| Q4 2024 | 27.7% | — | — |
Q2 2026 at a glance
TG Therapeutics, Q2 2026: revenue $240M (+70% year over year), operating margin 9.0%, net earnings $7.8M, operating cash flow $39.3M. The chart follows the revenue to costs, profit and cash.
Questions
What is TG Therapeutics' operating margin?
TG Therapeutics' operating margin was 9.0% in Q2 2026 (second quarter 2026), -8.0 pts from Q1 2026.
How has TG Therapeutics' operating margin changed?
Over the last 7 quarters it ranged from 7.1% (Q1 2025) to 27.7% (Q4 2024).